Sujet(s)
Acétaminophène/usage thérapeutique , Analgésiques non narcotiques/usage thérapeutique , Douleur/traitement médicamenteux , Neuropathies périphériques/complications , Acétaminophène/administration et posologie , Amputation chirurgicale , Analgésiques non narcotiques/administration et posologie , Analgésiques morphiniques/administration et posologie , Analgésiques morphiniques/usage thérapeutique , Humains , Perfusions veineuses , Mâle , Adulte d'âge moyen , Morphine/administration et posologie , Morphine/usage thérapeutique , Douleur/étiologie , Thromboangéite oblitérante/complicationsSujet(s)
Analgésiques non narcotiques/administration et posologie , Dexmédétomidine/administration et posologie , Tumeurs/complications , Douleur/traitement médicamenteux , Sujet âgé , Analgésie péridurale/méthodes , Analgésiques morphiniques/administration et posologie , Association de médicaments , Humains , Mâle , Morphine/administration et posologie , RécidiveRÉSUMÉ
PURPOSE: To evaluate the success of a new guidance device for sacroiliac joint puncture. MATERIAL AND METHODS: The device was first tested on a human anatomical model and thereafter on two groups of patients. In the first group (n=8), the traditional hand-guided method was used, and in the second group (n=10) the needle-holder device. The parameters evaluated in each group were "the number of attempts", defined as the number of skin punctures, and "fluoroscopy-injection time", defined as the time from the beginning of the fluoroscopy to the end of the correct insertion of the needle into the joint. RESULTS: Sacroiliac injection with the new device required significantly fewer attempts (2.1 +/- 2 versus 4.3 +/- 3) and shorter fluoroscopy injection times (8.9 +/- 3 min versus 15 +/- 5 min; P<0.05). CONCLUSION: The new guidance device makes sacroiliac joint injection easier and prevents unnecessary exposure to radiation during the procedure.
